X
[{"orgOrder":0,"company":"St. Jude Children","sponsor":"Blue Water Vaccines","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Blue Water Licenses Patent Rights for bacterial Vaccine Development","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"St. Jude Children"},{"orgOrder":0,"company":"Safety Shot","sponsor":"Applied Biology","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jupiter Wellness Initiates Clinical Trial for Potential New Treatment for Tinnitus","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Safety Shot"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Filters
Details:
This study aims to investigate if the dopamine receptor antagonist Pimozide can be used effectively treat COVID-19 for tinnitus, emergent symptoms lasting longer than 4 weeks since onset.
Lead Product(s):
Pimozide
Therapeutic Area: Otolaryngology (Ear, Nose, Throat)
Product Name: JW-600
Highest Development Status: Undisclosed
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Applied Biology
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
October 06, 2022
Details:
Blue Water Vaccines has entered into an exclusive worldwide license agreement for the development of a Streptococcus Pneumoniae vaccine with St. Jude Children's Research Hospital.
Lead Product(s):
Streptococcus Pneumoniae vaccine
Therapeutic Area: Otolaryngology (Ear, Nose, Throat)
Product Name: Undisclosed
Highest Development Status: Undisclosed
Product Type: Vaccine
Partner/Sponsor/Collaborator:
Blue Water Vaccines
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Licensing Agreement
February 10, 2020